Cardiovascular diseases (CVD) are the most common cause of death in Europe and worldwide. Although omega-3 polyunsaturated fatty acids (PUFA) are traditionally considered beneficial in CVD prevention, clinical trials have generated contradictory results for CVD outcomes. The aim of this project is to generate a personalised CVD prevention decision tool to identify responders and non-responders to omega-3 treatment. This project will explore observational cohorts and clinical trials for the interactions between genes, omega-3 PUFA treatment and/or intake, CVD risk factors, and biomarkers, followed by data integration for artificial intelligence (AI)-empowered development of the OmegaPerMed decision tool. The resulting personalised omega-3 treatment indications in CVD can be the first personalised medicine to be widely implemented in international CVD treatment guidelines to the benefit of a large patient population.